macrolides is seen (11). The mechanism of erythromycin resistance involves active efflux. The rate of isolation of strains with this novel phenotype among the erythromycin-resistant GAS of our work is even higher than that recently reported in the United States (75%) (11), although the incidence of erythromycin-resistant GAS is rare in this country (3) . However, 50% of erythromycin-resistant GAS isolated in Japan (5) and in Taiwan (4) were also resistant to clindamycin and tetracycline.
In conclusion, our report documents the emergence of high rates of resistance to erythromycin in S. pyogenes in Spain. Strains with the M phenotype account for the majority of those isolates, which in a sample of this size represents a significant finding. Clindamycin remained active against these strains and might be useful for treatment of patients with clinical failure after phenoxymethyl penicillin treatment and for penicillinallergic patients. We suggest that clinical laboratories review their local susceptibility data. If erythromycin resistance rates are high, we recommend that susceptibilities to both macrolides and clindamycin in S. pyogenes isolates be routinely tested. 
Synergistic Activity of Trovafloxacin and Ceftriaxone or Vancomycin against Streptococcus pneumoniae with Various Penicillin Susceptibilities
While interest in Streptococcus pneumoniae has always been high because of its role as a frequent pathogen, the increasing prevalence of penicillin-resistant isolates is of growing concern (2, 9). Rising resistance rate coupled with the failure of monotherapy for meningitis due to these isolates now warrant that empirical therapy consist of ceftriaxone and vancomycin (5, 7, 8) . Trovafloxacin, a new fluoroquinolone, has displayed exceptional activity against pneumococci and penetrates well into the cerebrospinal fluid (CSF) (1, 4) . Although its role in treatment of pneumococcal meningitis is currently under investigation, its synergistic potential with currently utilized therapies is unknown.
Forty-seven clinical isolates of S. pneumoniae with various susceptibilities to penicillin were studied (penicillin-susceptible, MIC of Յ0.06 g/ml The MIC for each drug-organism combination was determined in duplicate by using standard microdilution methods in ambient air. Synergy studies were undertaken by using the microdilution checkerboard technique. Bacterial dilutions in the logarithmic growth phase were prepared and pipetted into microtiter trays containing concentrations of each antibiotic which ranged from four to five times below the MIC to two times above the MIC. The final inoculum size, confirmed by colony count determinations, for all experiments was 5 ϫ 10 5 CFU/ml. Prepared microtiter trays were incubated at 37°C for 24 h, after which the trays were read for inhibition of bacterial growth. Fractional inhibitory concentration (FIC) indices were calculated according to the method of Eliopoulos and Moellering (3). Individual checkerboard runs were repeated five times for each isolate-drug combination, an FIC index was calculated for each, and an overall mean FIC index was determined. Synergy was defined as an FIC of Յ0.5, indifference was defined as an FIC of Ͼ0.5 to Յ4, and antagonism was defined as an FIC of Ͼ4.
The median and range of MICs of each agent are displayed in Table 1 . MICs of trovafloxacin and vancomycin were unaffected by penicillin susceptibility, whereas ceftriaxone MICs increased with increasing penicillin resistance. The in vitro interactions between trovafloxacin and ceftriaxone or trovafloxacin and vancomycin against the isolates are characterized in Table 2 . Synergy ws observed in 55 and 15% of the isolates treated with the trovafloxacin and ceftriaxone or trovafloxacin and vancomycin, respectively. Antagonism was not observed. In addition, synergy was observed for 13 of 17 isolates in the trovafloxacin and ceftriaxone studies when organisms were intermediate or resistant (i.e., MIC of Ͼ0.5 g/ml) to ceftriaxone.
Trovafloxacin has been shown to penetrate well into the CSF of healthy subjects, and concentrations that exceed the MICs for the most common organisms implicated in bacterial meningitis are maintained at this site (1) . In addition, trovafloxacin has displayed excellent penetration and bactericidal activity within the CSF of rabbits with experimental meningitis due to a highly penicillin-resistant S. pneumoniae isolate (6). Al- 
